Product nameAnti-MEK1 antibody [E342] (HRP)
See all MEK1 primary antibodies
DescriptionRabbit monoclonal [E342] to MEK1 (HRP)
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Cow
Synthetic peptide within Human MEK1 aa 1-100 (N terminal). The exact sequence is proprietary.
Database link: Q02750
- WB: A431 cells and cell lysate. IHC-P: FFPE human colon tissue sections.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Anti-MEK1 antibody [E342] (Alexa Fluor® 488) (ab193985)
- Anti-MEK1 antibody [E342] (Alexa Fluor® 647) (ab193986)
- Anti-MEK1 antibody [E342] (Phycoerythrin) (ab210618)
- Anti-MEK1 antibody [E342] (Alexa Fluor® 568) (ab214382)
- Anti-MEK1 antibody [E342] - BSA and Azide free (ab239802)
- Anti-MEK1 antibody [E342] (ab32091)
Our Abpromise guarantee covers the use of ab193987 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 45 kDa (predicted molecular weight: 43 kDa).|
|IHC-P||1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
Tissue specificityWidely expressed, with extremely low levels in brain.
Involvement in diseaseDefects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain.
modificationsPhosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
- Information by UniProt
- Dual specificity mitogen activated protein kinase kinase 1 antibody
- Dual specificity mitogen-activated protein kinase kinase 1 antibody
- ERK activator kinase 1 antibody
All lanes : Anti-MEK1 antibody [E342] (HRP) (ab193987) at 1/5000 dilution
Lane 1 : Wild-type HAP1 whole cell lysate
Lane 2 : MAP2K1 (MEK1) knockout HAP1 whole cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 43 kDa
Observed band size: 43 kDa
Exposure time: 1 minute
ab193987 was shown to recognize MEK1 in wild-type HAP1 cells as signal was lost at the expected MW in MAP2K1 (MEK1) knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and MAP2K1 (MEK1) knockout samples were subjected to SDS-PAGE. Ab193987 and ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/5000 dilution and 1/1000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.
IHC image of MEK1 staining in a section of formalin-fixed paraffin-embedded human normal colon*. The section was pre-treated using pressure cooker heat mediated antigen retrieval with sodium citrate buffer (pH6) for 30mins, and incubated overnight at +4°C with ab193987 at a working dilution of 1/500. DAB was used as the chromogen (ab103723), diluted 1/100 and incubated for 10min at room temperature. The section was counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
Anti-MEK1 antibody [E342] (HRP) (ab193987) at 1/5000 dilution + A431 (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 43 kDa
Observed band size: 45 kDa why is the actual band size different from the predicted?
Exposure time: 10 seconds
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab193987 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab193987 has not yet been referenced specifically in any publications.